Direct-acting oral anticoagulants in antiphospholipid syndrome
Antiphospholipid syndrome is an acquired autoimmune thrombophilia characterized by the development of recurrent vascular thrombosis of any caliber and type or obstetric pathology and the mandatory identification of persistently positive antiphospholipid antibodies. The main drug in the treatment of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2021-01-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2972 |
| Summary: | Antiphospholipid syndrome is an acquired autoimmune thrombophilia characterized by the development of recurrent vascular thrombosis of any caliber and type or obstetric pathology and the mandatory identification of persistently positive antiphospholipid antibodies. The main drug in the treatment of patients with antiphospholipid syndrome is warfarin. The role of direct-acting oral anticoagulants in the treatment of antiphospholipid syndrome remains controversial. The article discusses modern data on the place of direct-acting oral anticoagulants in the treatment of antiphospholipid syndrome. |
|---|---|
| ISSN: | 1995-4484 1995-4492 |